(E)-N-(2-(dimethylamino)ethyl)-3-(6-((E)-(5-methoxy-2-oxoindolin-3-ylidene)methyl)-1H-indazol-3-yl)-N-methylacrylamide 2,2,2-trifluoroacetate | 1168722-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: (E)-N-(2-(dimethylamino)ethyl)-3-(6-((E)-(5-methoxy-2-oxoindolin-3-ylidene)methyl)-1H-indazol-3-yl)-N-methylacrylamide 2,2,2-trifluoroacetate
• 英文别名: (E)-N-[2-(dimethylamino)ethyl]-3-[6-[(E)-(5-methoxy-2-oxo-1H-indol-3-ylidene)methyl]-1H-indazol-3-yl]-N-methylprop-2-enamide;2,2,2-trifluoroacetic acid
• CAS: 1168722-70-0
• 化学式: C₂HF₃O₂*C₂₅H₂₇N₅O₃
• 分子量: 559.545
• InChiKey: NIFJIUNGRMTBDH-DCPAZKNYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.73
• 重原子数：
  40
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  128
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：Pauls Heinz W.

  公开号：US20110065702A1

  公开（公告）日：2011-03-17

  The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，其结构式表示为(A)或其药学上可接受的盐。本发明还涉及一种药物组合物，包括上述结构式(A)所表示的化合物或其药学上可接受的盐，以及药学上可接受的载体或稀释剂。本发明还揭示了一种治疗患有癌症的受试者的方法，其中该方法包括给予上述结构式(A)所表示的化合物或其药学上可接受的盐的治疗有效量。
• US8765748B2
  申请人：——

  公开号：US8765748B2

  公开（公告）日：2014-07-01